1742. Vancomicyn-Resistant Enterococcus faecium Bacteraemia in a Tertiary Care Hospital: Antimicrobial Susceptibility, Clinical Features and Prognosis
Session: Poster Abstract Session: Treatment of Bacteremia and Endocarditis
Saturday, October 5, 2013
Room: The Moscone Center: Poster Hall C
Posters
  • IDWEEK 2.pdf (4.7 MB)
  • Background: Vancomycin-resistant Enterococcus faecium (VREF) has emerged as a relevant and potentially lethal etiology of health care-associated infections worldwide. The increasing rates of antimicrobial resistance, especially to the few existing therapeutic options, has made the VREF target of constant surveillance. The aim of this study was to asses the antimicrobial susceptibility pattern, the clinical characteristics and the prognosis of bloodstream infections by VREF in a tertiary care population.

    Methods:  All documented episodes of VREF bacteraemia identified between May 2010 and July 2012 were retrospectively analyzed. Antimicrobial susceptibilities, clinical characteristics and 30-day mortality rates were described.

    Results:  In total, 40 episodes of bloodstream infections by VREF were evaluated in the study period. All blood isolates were resistant to ampicillin and teicoplanin. The rates of resistance to gentamicin, quinopristin-dalfopristin, daptomycin and linezolid were 85.0% (34 of 40), 12.5% (5 of 40), 0% and 0%, respectively. The mean age of the patients was 44.5 years (± 22.0). Cancer was the most common underlying disease occurring in 37.5%(15 of 40) of all cases. The rate of ICU admission was 65% (26 of 40). The  mean APACHE-II score was 24.7 (± 7.7). The mean initial serum C-reactive protein and albumin levels were 167.5 mg/L (± 128.2) and 2.6 g/dL (± 0.68), respectively. The 30-day mortality rate was 62.5% (25 of 40).

    Conclusion: In spite of the favorable VREF susceptibility to daptomycin and linezolid, the 30-day mortality rates of patients with VREF bacteraemia was pronounced.

    Regis Rosa, M.D. M.S.1, Denise Machado, PhD2, Dariane Pereira2, Diego Boff2, Rodrigo Dos Santos, MD3 and Luciano Goldani, PhD, MD4, (1)PPG Em Ciências Médicas, Ufrgs - Faculty of Medicine, Porto Alegre, Brazil, (2)Ufrgs, Porto Alegre, Brazil, (3)Hospital De Clínicas De Porto Alegre, Porto Alegre, Brazil, (4)Infectious Diseases Unit, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil

    Disclosures:

    R. Rosa, None

    D. Machado, None

    D. Pereira, None

    D. Boff, None

    R. Dos Santos, None

    L. Goldani, None

    << Previous Abstract | Next Abstract

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.